The FDA’s transition from the long-standing Quality System Regulation (QSR) framework to the revised Quality Management System Regulation (QMSR) has become one of the most discussed regulatory changes within the medical device industry over the past two years.
Since the revised regulation aligns more closely with ISO 13485:2016, many manufacturers initially assumed that organizations already maintaining ISO 13485 certified quality systems would experience only minimal impact.
While the transition certainly moves toward greater harmonization, the practical implementation and inspection implications deserve closer attention.
A Shift Toward Global Alignment
On February 2, 2024, FDA published the final rule revising 21 CFR Part 820 and formally introducing the Quality Management System Regulation (QMSR). The revised regulation became effective on February 2, 2026.
Under the revised framework, FDA incorporated ISO 13485:2016 by reference into Part 820.
The intent behind this transition is to improve global harmonization of medical device quality management systems. For many years, manufacturers operating across multiple markets maintained separate or parallel quality system structures to address both FDA Quality System Regulation (QSR) requirements and ISO 13485 expectations adopted by various international regulatory authorities, often resulting in duplication in documentation, processes, and compliance activities.
The revised QMSR is therefore an important step toward improving global consistency in medical device quality management system expectations.
ISO 13485 Alignment Does Not Eliminate FDA Oversight
One important point manufacturers should clearly understand is that FDA has not replaced its regulatory oversight with ISO certification alone. FDA has clarified that ISO 13485 certification is not mandatory under QMSR, FDA inspections will continue as part of its regulatory oversight activities, the agency will not issue ISO 13485 certificates, and possession of an ISO 13485 certificate does not exempt a manufacturer from FDA inspections.
In practice, the revised framework can be viewed as:
QMSR = ISO 13485 framework + FDA-specific regulatory requirements
This distinction is important because many organizations continue assuming that an existing ISO certificate automatically demonstrates FDA inspection readiness.
Areas Likely to Require Additional Attention
For manufacturers already operating under mature ISO 13485 quality management systems, several existing quality system elements may already substantially align with the revised QMSR framework. However, organizations should still carefully reassess key operational areas such as complaint handling processes, MDR evaluation linkage, supplier qualification activities, internal audit documentation, management review evidence, traceability practices, CAPA effectiveness, process validation documentation, and record retention practices. FDA has also clarified that records previously exempt from routine review under earlier QS Regulation provisions may now be reviewed during FDA inspections conducted under QMSR, including internal audit records, management review documentation, and supplier audit reports. For some organizations, this may represent one of the more operationally significant inspection-related changes introduced under the revised framework.
Changes to FDA Inspection Approach
Another important development under QMSR is the transition away from the historical Quality System Inspection Technique (QSIT) methodology previously used during FDA inspections. FDA confirmed that from February 2, 2026, inspections are conducted under the updated Medical Device Manufacturers Compliance Program 7382.850 aligned with QMSR requirements. As a result, manufacturers should avoid preparing solely against historical QSIT expectations and instead evaluate inspection readiness against the revised ISO 13485-aligned quality management framework adopted within QMSR.
Impact on Documentation and Terminology
The transition also introduces several terminology and structural changes aligned with ISO 13485 conventions. Manufacturers may increasingly encounter terminology associated with Medical Device File structures, Design and Development Files, and other ISO-aligned documentation approaches instead of several legacy FDA terms historically used under the earlier QSR framework. Although the underlying quality management principles remain largely familiar, organizations may still need to update procedures, quality manuals, templates, training materials, and internal documentation structures to improve alignment with the revised QMSR framework and ISO-based terminology expectations.
Considerations for Software and Digital Health Manufacturers
Manufacturers developing Software as a Medical Device (SaMD), connected devices, software-enabled systems, or AI-driven technologies should evaluate QMSR implementation together with broader FDA expectations around software lifecycle management and cybersecurity.
While QMSR establishes the overall quality management system framework, organizations developing software-driven medical technologies should continue reviewing applicable FDA software validation guidance, cybersecurity guidance, IEC 62304 software lifecycle expectations, and ISO 14971 risk management activities as part of their compliance approach. In practice, FDA expectations related to software validation, traceability, lifecycle documentation, cybersecurity controls, and risk management integration continue to remain highly relevant for Software as a Medical Device (SaMD), connected devices, and other software-enabled medical technologies.
Practical Industry Perspective
From a practical standpoint, manufacturers with mature, well-integrated ISO 13485 systems are generally expected to experience a smoother transition toward QMSR compliance compared to organizations operating with fragmented or minimally mature quality systems.
Organizations that previously maintained separate quality system approaches for FDA QSR, ISO 13485, MDSAP, or EU MDR requirements may now benefit from improved harmonization and reduced duplication under the revised QMSR framework. At the same time, organizations operating with weak documentation practices, limited supplier oversight, underdeveloped CAPA systems, insufficient risk management integration, or limited inspection preparedness may still require significant remediation activities to strengthen overall compliance readiness before future FDA inspections.
How MedOrdyn Solutions Supports Manufacturers
At MedOrdyn Solutions, we support medical device manufacturers across regulatory, quality, and compliance activities throughout the product lifecycle.
Our support areas include QMSR transition gap assessments, ISO 13485 implementation and remediation, FDA inspection readiness support, quality documentation review, design control and traceability assessment, CAPA and risk management evaluation, supplier quality system review, and support for software-driven medical technologies and Software as a Medical Device (SaMD) compliance activities.
With experience across FDA regulatory requirements, ISO 13485 quality systems, EU MDR compliance, and software lifecycle regulatory expectations, our focus is on helping manufacturers strengthen practical and inspection-ready quality management systems aligned with evolving global regulatory expectations.
Conclusion
FDA’s transition from the historical QSR framework toward the revised Quality Management System Regulation represents an important milestone in the broader movement toward internationally harmonized medical device quality system expectations.
While the revised framework significantly aligns FDA requirements with ISO 13485:2016, manufacturers should clearly recognize that FDA inspection authority and regulatory oversight continue to remain fully applicable.
Rather than viewing the transition as only a terminology update, organizations should use this opportunity to reassess quality system maturity, strengthen operational effectiveness, improve inspection readiness, and align more effectively with evolving global regulatory expectations.
References
- FDA Quality Management System Regulation (QMSR)
- FDA Final Rule: Medical Devices; Quality System Regulation Amendments
- 21 CFR Part 820 – Quality Management System Regulation
- ISO 13485:2016 – Medical Devices Quality Management Systems
- FDA QMSR Frequently Asked Questions (FAQ)
